Subscribe to Imaging
View Sample

FREE Email Newsletter

Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study i...

December 19, 2010 11:32 pm | by Bio-Medicine.Org | News | Comments

TARRYTOWN, N.Y., Dec. 20, 2010 /- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time on Monday, December 20, to discuss results of the Phase 3 COPERNICUS study with VEGF Trap-Eye in central retinal vein...

An ITG Majestic Market Research Study Indicates a Bright Future for Gilenya, Despite Concerns About Its Safety

December 17, 2010 7:31 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Dec. 17, 2010 /- A study published this week by ITG (NYSE: ITG ) revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year.  ...

Drug Combinations That May Cause Major Drug Interactions Common Among Seniors Who Take Antidepressants, According to Thomson Reuters Research

December 17, 2010 2:31 am | by Bio-Medicine.Org | News | Comments

ANN ARBOR, Mich., Dec. 17, 2010 /- More than half of older Americans who were prescribed antidepressants for the first time were already taking a medication that could adversely interact with the antidepressant , according to a new study from Thomson Reuters. For one-fourth of the seniors...


Jennerex and Transgene Announce Initiation of Clinical Trial of Intravenous JX-594 in Patients With Refractory Metastatic Colorectal Cancer

December 15, 2010 11:32 pm | by Bio-Medicine.Org | News | Comments

SAN FRANCISCO and ILLKIRCH, France, Dec. 16, 2010 /- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a...

Watson and Richter Announce Exclusive License Agreement for Esmyaâ„¢

December 15, 2010 11:32 pm | by Bio-Medicine.Org | News | Comments

MORRISTOWN, N.J., and BUDAPEST, HUNGARY, Dec. 16, 2010 /- Watson Pharmaceuticals, Inc. (NYSE: WPI ) ("Watson") and Gedeon Richter Plc ("Richter") today announced that Watson's subsidiary, Watson Laboratories, Inc. has entered into an exclusive licensing agreement with PregLem, S.A.,...

SABCS 2010 Interview with Amelie G. Ramirez, Dr.P.H.

December 15, 2010 1:33 pm | by AACR | News | Comments

Dr. Ramirez discusses the importance of genetic testing for breast cancer among Latinas, statewide and national communications programs, challenges facing the Hispanic community in reference to cancer, and how to address some of these concerns.

CyberKnife Centers of Miami and Palm Beach Announce New Chief Operating Officer

December 15, 2010 10:36 am | by Bio-Medicine.Org | News | Comments

MIAMI, Dec. 15, 2010 /- James G. Schwade, M.D., Executive Director of the CyberKnife Centers of Miami and Palm Beach, ( ) is pleased to announce the appointment of Gail Suarez as the Chief Operating Officer. (Photo:...

SABCS Interview with Peter M. Ravdin, M.D., Ph.D.

December 15, 2010 10:36 am | by AACR | News | Comments

Dr. Ravdin talks about his work with SABCS, notable abstracts being presented, and his vision for the future of the SABCS.


Control Risks Forecasts New Reality for Business in 2011 Brought by Emerging Markets, Legislation

December 15, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, Dec. 15, 2010 /PRNewswire-USNewswire/ -- Control Risks , one of the world's leading business risk consultancies, today launches RiskMap 2011 – its annual review and forecast of business risk for the year ahead, including regional outlooks, and a rating of political and...

RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group

December 15, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

LAKE FOREST, Ill., Dec. 15, 2010 /- RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has entered into a definitive agreement to sell one of its portfolio companies, Clinical...

Pharmaceutical Institute Hires Nathan Pienkowski, Ph.D., to Head Instructional Design

December 15, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

RALEIGH, N.C., Dec. 15, 2010 /- Pharmaceutical Institute, a leading provider of specialized training solutions for the pharmaceutical and biotech industry and a subsidiary of Campbell Alliance, has appointed Nathan Pienkowski, Ph.D., as Instructional Design Director.  In this role,...

Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee

December 15, 2010 7:34 am | by Bio-Medicine.Org | News | Comments

NEW BRUNSWICK, N.J., Dec. 15, 2010 /- Johnson & Johnson (NYSE: JNJ ) today announced that Alex Gorsky, currently Worldwide Chairman, Medical Devices & Diagnostics (MD&D) and Sheri McCoy, currently Worldwide Chairman, Pharmaceuticals, have been appointed Vice Chairmen of the...

NASDAQ Gives Dynatronics a Second Six-Month Extension for Minimum Bid Price Compliance

December 15, 2010 7:33 am | by Bio-Medicine.Org | News | Comments

SALT LAKE CITY, Dec. 15, 2010 /- Dynatronics Corporation (Nasdaq: DYNT ) today announced that NASDAQ has given the company until June 13, 2011, to comply with its $1 per share minimum bid rule. "Given the challenges of the general economy, we welcome the grant by NASDAQ of an additional...


DSM Expands Industrial Biocatalysis Platform With c-LEcta Agreement

December 14, 2010 10:34 pm | by Bio-Medicine.Org | News | Comments

PARSIPPANY, N.J. and LEIPZIG, Germany, Dec. 15 2010 /- DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, today announces a license agreement with c-LEcta GmbH for proprietary screening technology. The agreement grants DSM rights to c-LEcta's proprietary...

UBM Canon Launches Medical Manufacturing Events in India and Brazil

December 14, 2010 9:35 am | by Bio-Medicine.Org | News | Comments

LOS ANGELES, Dec. 14, 2010 /- UBM Canon today announced medical manufacturing event plans for two fast-growth BRIC markets, India and Brazil, utilizing respectively its long established MEDTEC and Medical Design & Manufacturing (MD&M) brands. In October 19-20, 2011, the MEDTEC...

Verenium Announces 2010 Business Update and Outlook for 2011

December 14, 2010 6:39 am | by Bio-Medicine.Org | News | Comments

CAMBRIDGE, Mass., Dec. 14, 2010 /- Verenium Corporation (Nasdaq: VRNM ), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced key 2010 accomplishments and 2011 Company goals and financial guidance. "2010 has been a significant...

Cannabis Science Signs Lease for New 6,600 sq. ft. Corporate Headquarters and Laboratory Facility

December 14, 2010 12:39 am | by Bio-Medicine.Org | News | Comments

COLORADO SPRINGS, Colo., Dec. 14, 2010 /- Cannabis Science, Inc. (OTC Bulletin Board: CBIS ) a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce it has signed a lease for a new corporate headquarters as its new base of operations in...

Natural Orifice Surgery Introduced to Relieve Acid Reflux

December 13, 2010 10:36 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Dec. 13, 2010 /PRNewswire-USNewswire/ -- Montefiore Medical Center has introduced a natural orifice surgery through the mouth, to relieve gastroesophageal reflux disease (GERD), most commonly known as acid reflux. Since this natural orifice transluminal endoscopic surgery...

iLeverage Announces the Successful Sale of the BICO Patent Portfolio for Near-Infrared Non-Invasive Blood Analytes Measurement

December 13, 2010 1:32 am | by Bio-Medicine.Org | News | Comments

SAN FRANCISCO, Dec. 13, 2010 /- iLeverage ( ), a leading patent broker, today announced the successful closing of the Biocontrol patent portfolio sale. The patents were offered to companies that participate in the relevant markets as well as to a number of IP licensing...

Young Children In Developing World Receive Accelerated Access to Pfizer's Prevenar 13 Vaccine

December 12, 2010 2:32 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Dec. 12, 2010 /- Pfizer Inc. (NYSE: PFE ) announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of...

SABCS 2010: Interview with C. Kent Osborne, M.D.(2)

December 11, 2010 5:35 pm | by AACR | News | Comments

Dr. Osborne talks about the most compelling research presented at the symposium this year, his long association with the SABCS and his vision for its future.

SABCS 2010: Interview with Eric P. Winer, M.D.

December 11, 2010 12:31 pm | by AACR | News | Comments

SABCS 2010: Interview with Eric P. Winer, M.D., director of the Breast Oncology Center and Thompson senior investigator in breast cancer research at Dana-Farber Cancer Institute; professor of Medicine at Harvard Medical School Dr. Winer discusses breast cancer screening, the clinical...

SABCS 2010: Interview with Robert E. Coleman, M.D.

December 11, 2010 10:31 am | by AACR | News | Comments

Dr. Coleman, chief investigator of the AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence) trial, presents the rationale for studying the bisphosphonate zoledronic acid, and the final results of this study.

SABCS 2010: Interview with Paul Workman, Ph.D., F.Med.Sci.

December 11, 2010 6:37 am | by AACR | News | Comments

Dr. Workman defines molecular chaperones and discusses their role in the cell, stress response pathways, heat shock proteins and the potential of this line of breast cancer research.

SABCS 2010: Interview with Rowan T. Chlebowski, M.D. Ph.D.

December 11, 2010 6:36 am | by AACR | News | Comments

Dr. Chlebowski, lead investigator for the Women's Health Initiative, discusses the initiative's findings about the use of hormone therapy and its influence on cancer incidence and related cancer mortality, and the effects of bisphosphonates on breast cancer risk.

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.